 |
471 Diseases |  |
207 Trials |
|
207 Trials |  |
10577 News |  |
| «12...121122123124125126127128129130131...132133» |
- everolimus / Generic mfg.
Enrollment change: Everolimus Rescue Immunosuppression in the Treatment of Chronic Allograft Dysfunction in Renal Transplant Recipients (clinicaltrials.gov) - Jul 2, 2013
P4, N=17, Completed, Sponsor: Chinese University of Hong Kong
N=30 --> 17
- everolimus / Generic mfg.
Trial completion: Everolimus Rescue Immunosuppression in the Treatment of Chronic Allograft Dysfunction in Renal Transplant Recipients (clinicaltrials.gov) - Jul 2, 2013
P4, N=17, Completed, Sponsor: Chinese University of Hong Kong
N=30 --> 17 Recruiting --> Completed
- Fumena (vorolanib) / Tyrogenex, Betta Pharma
Enrollment open: VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Everolimus for Treating Patients With Pancreatic Neuroendocrine Tumors (clinicaltrials.gov) - Jul 1, 2013
P1/2, N=50, Recruiting, Sponsor: Washington University School of Medicine
Recruiting --> Completed Not yet recruiting --> Recruiting
- Enrollment change: Study of RAD001 in Patients With Relapsed/Refractory Hodgkin Lymphoma That Has Progressed After High-dose Chemotherapy and Autologous Stem Cell Transplant and/or After Gemcitabine- or Vinorelbine- or Vinblastine-based Treatment. (clinicaltrials.gov) - Jun 30, 2013
P2, N=57, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting N=73 --> 57
- Avastin (bevacizumab) / Roche
Trial completion: RT, Temozolomide, and Bevacizumab Followed by Bevacizumab/Everolimus in First-line Treatment of GBM (clinicaltrials.gov) - Jun 30, 2013
P2, N=68, Completed, Sponsor: SCRI Development Innovations, LLC
N=73 --> 57 Active, not recruiting --> Completed
- ||||| Trial initiation date: The Everolimus-Transplant Exit Strategy Trial (E-TEST) (clinicaltrials.gov) - Jun 27, 2013
P3, N=60, Recruiting, Sponsor: Allan D Kirk, MD, PhD
Active, not recruiting --> Completed Initiation date: Jan 2013 --> Jun 2013
- |||| Enrollment open: Certican (Everolimus) for Recipients of Kidney From HLA-identical Living Donors (clinicaltrials.gov) - Jun 27, 2013
P4, N=100, Recruiting, Sponsor: Hospital do Rim e Hipertensão
Initiation date: Jan 2013 --> Jun 2013 Not yet recruiting --> Recruiting
- |||||| Enrollment open: The Everolimus-Transplant Exit Strategy Trial (E-TEST) (clinicaltrials.gov) - Jun 27, 2013
P3, N=60, Recruiting, Sponsor: Allan D Kirk, MD, PhD
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Enrollment closed: EVEROLD: mTor-inhibitor (EVERolimus) Based Immunosuppressive Strategies for CNI Minimisation in OLD for Old Renal Transplantation (clinicaltrials.gov) - Jun 27, 2013
P3, N=306, Active, not recruiting, Sponsor: University Hospital, Brest
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Enrollment closed: Efficacy and Safety of Induction Strategies Combined With Low Tacrolimus Exposure in Kidney Transplant Recipients Receiving Everolimus or Sodium Mycophenolate (clinicaltrials.gov) - Jun 27, 2013
P4, N=300, Active, not recruiting, Sponsor: Hospital do Rim e Hipertens
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- cisplatin / Generic mfg., everolimus / Generic mfg., paclitaxel / Generic mfg.
Enrollment closed, Metastases: Cisplatin and Paclitaxel With or Without Everolimus in Treating Patients With Stage II or Stage III Breast Cancer (clinicaltrials.gov) - Jun 26, 2013
P2, N=145, Active, not recruiting, Sponsor: Vanderbilt-Ingram Cancer Center
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- |||||||||| everolimus / Generic mfg.
New P3 trial: Efficacy and Safety of Everolimus in Liver Transplant Recipients of Living Donor Liver Transplants (clinicaltrials.gov) - Jun 25, 2013
P3, N=470, Recruiting, Sponsor: Novartis Pharmaceuticals
- | everolimus / Generic mfg.
New P2 trial, Metastases: POORTOR: Assessing Everolimus in Fist Line Treatment on Patients With Metastatic Kidney Cancer (clinicaltrials.gov) - Jun 25, 2013
P2, N=90, Recruiting, Sponsor: Gustave Roussy, Cancer Campus, Grand Paris
- everolimus / Generic mfg.
Enrollment open, Metastases: POORTOR: Assessing Everolimus in Fist Line Treatment on Patients With Metastatic Kidney Cancer (clinicaltrials.gov) - Jun 24, 2013
P2, N=90, Recruiting, Sponsor: Gustave Roussy, Cancer Campus, Grand Paris
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- prednisone / Generic mfg., everolimus / Generic mfg., mycophenolate sodium / Generic mfg.
Enrollment open, IO biomarker: Renal Transplantation in the Elderly - nEverOld Study (clinicaltrials.gov) - Jun 19, 2013
P4, N=90, Recruiting, Sponsor: University of Sao Paulo General Hospital
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- everolimus / Generic mfg., nintedanib / Generic mfg.
Trial initiation date: BARIS: BIBF 1120 and RAD001 in Solid Tumors - Phase I (clinicaltrials.gov) - Jun 17, 2013
P1, N=18, Recruiting, Sponsor: University of Cologne
Not yet recruiting --> Recruiting Initiation date: May 2011 --> Jul 2012
- everolimus / Generic mfg., nintedanib / Generic mfg.
Enrollment open: BARIS: BIBF 1120 and RAD001 in Solid Tumors - Phase I (clinicaltrials.gov) - Jun 17, 2013
P1, N=18, Recruiting, Sponsor: University of Cologne
Initiation date: May 2011 --> Jul 2012 Not yet recruiting --> Recruiting
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed, Metastases: A Study of Carboplatin, Cetuximab and RAD001 in Advanced Head and Neck Cancer (clinicaltrials.gov) - Jun 16, 2013
P1/2, N=48, Active, not recruiting, Sponsor: Emory University
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- New P2/3 trial: A Pilot Study Comparing the Safety and Efficacy of Everolimus With Other Medicines in Recipients of ECD/DCD Kidneys (clinicaltrials.gov) - Jun 13, 2013
P2/3, N=50, Active, not recruiting, Sponsor: Matthew Cooper
- ||| Enrollment change: SOCRATES: Steroid or Cyclosporine Removal After Transplantation Using Everolimus (clinicaltrials.gov) - Jun 12, 2013
P4, N=126, Completed, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting N=177 --> 126
- everolimus / Generic mfg.
Trial termination: Study of Everolimus in de Novo Renal Transplant Recipients (clinicaltrials.gov) - Jun 10, 2013
P=N/A, N=1, Terminated, Sponsor: Helady Pinheiro, MD, PhD
N=177 --> 126 Recruiting --> Terminated; The inclusion of proposed sample turned to be infeasible due to Ethical Non-approval of 2 research sites and another site no transplant activity since 2012.
- everolimus / Generic mfg.
Enrollment change: Study of Everolimus in de Novo Renal Transplant Recipients (clinicaltrials.gov) - Jun 10, 2013
P=N/A, N=1, Terminated, Sponsor: Helady Pinheiro, MD, PhD
Recruiting --> Terminated; The inclusion of proposed sample turned to be infeasible due to Ethical Non-approval of 2 research sites and another site no transplant activity since 2012. N=70 --> 1
- ||| BNC105 / Bionomics
Enrollment closed, Combination therapy, Metastases: BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma (clinicaltrials.gov) - Jun 6, 2013
P2, N=152, Active, not recruiting, Sponsor: Hoosier Oncology Group
N=70 --> 1 Recruiting --> Active, not recruiting
- Avastin (bevacizumab) / Roche
Enrollment open: Sequential Two-agent Assessment in Renal Cell Carcinoma Therapy: The START Trial (clinicaltrials.gov) - Jun 4, 2013
P2, N=240, Recruiting, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Active, not recruiting Active, not recruiting --> Recruiting
- ||||||| Trial completion: CERTITEM: Progression of Renal Interstitial Fibrosis / Tubular Atrophy (IF/TA) According to Epithelial-mesenchymal Transition (EMT) and Immunosuppressive Regimen (Everolimus Based Versus CNI Based) in de Novo Renal Transplant Recipients (clinicaltrials.gov) - Jun 3, 2013
P3, N=194, Completed, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Recruiting Recruiting --> Completed
- everolimus / Generic mfg., docetaxel / Generic mfg.
Trial completion, Metastases: The Use of RAD001 With Docetaxel in the Treatment of Metastatic, Androgen Independent Prostate Cancer (clinicaltrials.gov) - Jun 3, 2013
P1/2, N=60, Completed, Sponsor: Dana-Farber Cancer Institute
Recruiting --> Completed Active, not recruiting --> Completed
- |||||||||| Cabometyx (cabozantinib tablet) / Exelixis
New P3 trial, Metastases: METEOR: A Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma (clinicaltrials.gov) - May 29, 2013
P3, N=650, Recruiting, Sponsor: Exelixis
- everolimus / Generic mfg., paclitaxel / Generic mfg.
Enrollment change: Combination Anticancer Therapy of Paclitaxel and Everolimus for Relapsed or Refractory Small Cell Lung Cancer (clinicaltrials.gov) - May 28, 2013
P1, N=21, Completed, Sponsor: Samsung Medical Center
Active, not recruiting --> Completed N=15 --> 21
- everolimus / Generic mfg., paclitaxel / Generic mfg.
Trial completion: Combination Anticancer Therapy of Paclitaxel and Everolimus for Relapsed or Refractory Small Cell Lung Cancer (clinicaltrials.gov) - May 28, 2013
P1, N=21, Completed, Sponsor: Samsung Medical Center
N=15 --> 21 Recruiting --> Completed
- MK-2206 / Merck (MSD)
Enrollment closed: Akt Inhibitor MK2206 or Everolimus in Treating Patients With Refractory Kidney Cancer (clinicaltrials.gov) - May 27, 2013
P2, N=105, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Completed Suspended --> Active, not recruiting
- TheraSphere (yttrium 90 microspheres) / Boston Scientific
New P1 trial: Phase 1 TheraSphere + Everolimus With Neuroendocrine Tumors (NETs) + Liver Only or Liver Dominant Disease (clinicaltrials.gov) - May 27, 2013
P1, N=22, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
- Avastin (bevacizumab) / Roche
Enrollment closed: Bevacizumab With or Without Everolimus in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer (clinicaltrials.gov) - May 27, 2013
P2, N=150, Active, not recruiting, Sponsor: Gynecologic Oncology Group
Suspended --> Active, not recruiting Recruiting --> Active, not recruiting
- | prednisone / Generic mfg., everolimus / Generic mfg.
New P2a trial: PredEver first: Treatment of Newly Diagnosed Moderate or Severe Chronic Graft-versus-host Disease With Prednisone and Everolimus (clinicaltrials.gov) - May 23, 2013
P2a, N=60, Recruiting, Sponsor: Universitätsklinikum Hamburg-Eppendorf
- | imatinib / Generic mfg., everolimus / Generic mfg.
Enrollment change, Stroma: Radix: Treatment of Patients With Everolimus and Imatinib Mesylate Who Have Progressive Gastro Intestinal Stromal Tumors (GIST) and Are Resistant to Imatinib Mesylate (clinicaltrials.gov) - May 20, 2013
P4, N=27, Completed, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting N=53 --> 27
- | imatinib / Generic mfg., everolimus / Generic mfg.
Trial completion, Stroma: Radix: Treatment of Patients With Everolimus and Imatinib Mesylate Who Have Progressive Gastro Intestinal Stromal Tumors (GIST) and Are Resistant to Imatinib Mesylate (clinicaltrials.gov) - May 20, 2013
P4, N=27, Completed, Sponsor: Novartis Pharmaceuticals
N=53 --> 27 Active, not recruiting --> Completed
- ||||||| everolimus / Generic mfg., mycophenolate mofetil / Generic mfg.
Trial completion, Head-to-Head: Non-inferiority Study of Safety and Efficacy of Everolimus With Low Dose Tacrolimus to Mycophenolate Mofetil With Standard Dose Tacrolimus in Kidney Transplant Recipients (clinicaltrials.gov) - May 19, 2013
P3, N=613, Completed, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||| Kisqali (ribociclib) / Novartis
New P1/2 trial, Combination therapy, Metastases: Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast Cancer (clinicaltrials.gov) - May 16, 2013
P1/2, N=185, Recruiting, Sponsor: Novartis Pharmaceuticals
- ||||| sotrastaurin (AEB071) / Novartis
New P1/2 trial: COEB071X2103: Safety and Efficacy of AEB071 and EVEROLIMUS in Patients With CD79-mutant or ABC Subtype Diffuse Large B-Cell Lymphoma (clinicaltrials.gov) - May 13, 2013
P1/2, N=70, Recruiting, Sponsor: Novartis Pharmaceuticals
- everolimus / Generic mfg., sorafenib / Generic mfg.
New P1 trial: EVESOR: a Phase 1 Trial of Everolimus and Sorafenib (clinicaltrials.gov) - May 12, 2013
P1, N=60, Recruiting, Sponsor: Hospices Civils de Lyon
- Rituxan (rituximab) / Roche
Enrollment open: Maintenance Rituximab With mTor Inhibition After High-dose Consolidative Therapy in Lymphoma (clinicaltrials.gov) - May 9, 2013
P2, N=60, Recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- |||| Roferon A (recombinant interferon alfa-2a) / Roche, Avastin (bevacizumab) / Roche
Trial completion, Metastases: Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab for the First-line Treatment in Adult Patients With Kidney Cancer (clinicaltrials.gov) - May 9, 2013
P2, N=467, Completed, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | AEE788 / Novartis
Enrollment change, Combination therapy: AEE788 and Everolimus in Treating Patients With Recurrent or Relapsed Glioblastoma Multiforme (clinicaltrials.gov) - May 8, 2013
P1/2, N=16, Completed, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed N=22 --> 16
- Nulojix (belatacept) / BMS
Trial withdrawal: Calcineurin Inhibitor-free, Steroid-free Immunosuppressive Regimen in Simultaneous Islet-Kidney Transplantation for Uremic Type 1 Diabetic Patients (clinicaltrials.gov) - May 5, 2013
P=N/A, N=0, Withdrawn, Sponsor: University of Wisconsin, Madison
N=22 --> 16 Recruiting --> Withdrawn
- Votrient (pazopanib) / Novartis, BeiGene
Enrollment closed, Metastases: Pazopanib and Everolimus in PI3KCA Mutation Positive/PTEN Loss Patients (clinicaltrials.gov) - May 2, 2013
P1, N=62, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Withdrawn Recruiting --> Active, not recruiting
- |||| everolimus / Generic mfg., fulvestrant / Generic mfg.
Enrollment open, Metastases: Study of Fulvestrant +/- Everolimus in Post-Menopausal, Hormone-Receptor + Metastatic Breast Ca Resistant to AI (clinicaltrials.gov) - May 1, 2013
P2, N=130, Recruiting, Sponsor: PrECOG, LLC.
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- | AEE788 / Novartis
Trial completion, Combination therapy: AEE788 and Everolimus in Treating Patients With Recurrent or Relapsed Glioblastoma Multiforme (clinicaltrials.gov) - Apr 29, 2013
P1/2, N=16, Completed, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- ||||| New P4 trial, Combination therapy: 12 Month Athena Study: Everolimus vs. Standard Regimen in de Novo Kidney Transplant Patients (clinicaltrials.gov) - Apr 28, 2013
P4, N=612, Recruiting, Sponsor: Novartis Pharmaceuticals
- everolimus / Generic mfg., gefitinib / Generic mfg.
Trial completion, IO biomarker, Metastases: Everolimus and Gefitinib in Treating Patients With Progressive Glioblastoma Multiforme or Progressive Metastatic Prostate Cancer (clinicaltrials.gov) - Apr 25, 2013
P1/2, N=61, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||| Sutent (sunitinib) / Pfizer
Enrollment change, Metastases: A randomized study to explore the efficacy and feasibility of rotations between sunitinib and everolimus versus sequential treatment of sunitinib and everolimus until progression in patients with renal cancer. Estudio aleatorizado, para explorar la eficacia y la viabilidad de rotaciones entre sunitinib y everolimus, en comparaci (EUDRACT) - Apr 19, 2013
P2, N=115, Ongoing, Sponsor: APRO
Active, not recruiting --> Completed N=40 --> 115
- letrozole / Generic mfg., everolimus / Generic mfg.
Enrollment change: Phase II study of the combination of RAD001 and Letrozole in patients with recurrent endometrial cancer (EUDRACT) - Apr 19, 2013
P2, N=78, Terminated, Sponsor: Oncology Institute of Southern Switzerland
N=40 --> 115 N=30 --> 78